REGN

SAN FRANCISCO, July 29, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026.

New class action for Regeneron (REGN) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/14/2026

Time-Sensitive: Allegations focus on Regeneron's statements about clinical differentiation in the Phase III Fianlimab-Libtayo Study and the last-minute protocol amendment used to force a trial readout. NEW YORK, July 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) of a pending securities class action.

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) of the  September 14, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Regeneron Class Action Lawsuit : Do you, or did you, own shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)?

Biotech is setting up as one of the more interesting risk-on trades heading into the back half of 2026.

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and certain of the company's senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws. If you invested in Regeneron, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/regeneron-class-action-lawsuit.

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN).   Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

SAN FRANCISCO, July 28, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026.

New York, New York--(Newsfile Corp. - July 28, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between August 1, 2025 and May 15, 2026, both dates inclusive (the "Class Period").

Regeneron's Q2 results could hinge on Dupixent profits and strong Eylea HD, Libtayo sales as investors watch earnings, buybacks and pipeline updates.